Monoclonal antibody medication
Solanezumab (proposed INN , LY2062430[ 1] ) is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector [ 2] for patients with Alzheimer's disease .[ 3] [ 4] The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.[ 5] [ 6]
^ Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. (July 2012). "Safety and biomarker effects of solanezumab in patients with Alzheimer's disease". Alzheimer's & Dementia . 8 (4): 261–271. doi :10.1016/j.jalz.2011.09.224 . PMID 22672770 . S2CID 12755108 .
^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy) , World Health Organization .
^ Clinical trial number NCT00749216 for "Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease" at ClinicalTrials.gov
^ Clinical trial number NCT00905372 for "Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)" at ClinicalTrials.gov
^ McCartney M (July 2015). "Margaret McCartney: The "breakthrough" drug that's not been shown to help in Alzheimer's disease" . BMJ . 351 : h4064. doi :10.1136/bmj.h4064 . PMID 26208710 .
^ Meglio M (March 10, 2023). "Solanezumab Fails Phase 3 A4 Study of Preclinical Alzheimer Disease" . NeurologyLive . Retrieved August 1, 2023 .